{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:18:56Z","timestamp":1782775136006,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jaad.2021.07.054","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T18:44:47Z","timestamp":1628102687000},"page":"1274-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence"],"prefix":"10.1016","volume":"85","author":[{"given":"Sarah","family":"Wack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2021.07.054_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jaad.2021.07.054_bib2","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.vaccine.2017.01.048","volume":"35","author":"Croce","year":"2017","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.jaad.2021.07.054_bib3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMe2025111","article-title":"The Covid-19 vaccine-development multiverse","volume":"383","author":"Heaton","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2021.07.054_bib7","doi-asserted-by":"crossref","first-page":"108634","DOI":"10.1016\/j.clim.2020.108634","article-title":"COVID-19: a review of therapeutic strategies and vaccine candidates","volume":"222","author":"Izda","year":"2021","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2021.07.054_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: from SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jaad.2021.07.054_bib9","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3389\/fimmu.2020.01817","article-title":"The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies","volume":"11","author":"Frederiksen","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2021.07.054_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-020-01744-7","article-title":"The COVID-19 vaccine race: challenges and opportunities in vaccine formulation","volume":"21","author":"Wang","year":"2020","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.jaad.2021.07.054_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2021.07.054_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines: a\u00a0new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2021.07.054_bib13","doi-asserted-by":"crossref","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cPotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases\u201d","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin Immunol"},{"issue":"22","key":"10.1016\/j.jaad.2021.07.054_bib14","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jaad.2021.07.054_bib16","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/annrheumdis-2021-220231","article-title":"Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Connolly","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2021.07.054_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/vaccines9050435","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.jaad.2021.07.054_bib18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/ced.14631","article-title":"COVID-19 vaccination and patients with psoriasis under biologics: Real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers","volume":"46","author":"Damiani","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.07.054_bib19","doi-asserted-by":"crossref","first-page":"E542","DOI":"10.1016\/S2665-9913(21)00181-8","article-title":"Adverse events after first COVID-19 vaccination in patients with autoimmune diseases","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaad.2021.07.054_bib20","article-title":"Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2","author":"Deepak","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.jaad.2021.07.054_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.07.054_bib22","first-page":"1","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"0","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jaad.2021.07.054_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220289","article-title":"Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Boyarsky","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.07.054_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients\u00a0with rheumatic diseases","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.07.054_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.04.025","article-title":"Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological\u00a0therapies","volume":"161","author":"Wong","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2021.07.054_bib26","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2021.07.054_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients\u00a0receiving immunomodulators for immune-mediated inflammatory disease","author":"Al-Janabi","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.07.054_bib28","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","article-title":"Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of inflammatory bowel disease patients with diverse exposure to immunosuppressive medications","volume":"161","author":"Khan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2021.07.054_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220539","article-title":"Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'","author":"Ramirez","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.07.054_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220408","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response","author":"Bonelli","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jaad.2021.07.054_bib31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the\u00a0effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.07.054_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2021.07.054_bib39","article-title":"COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases","year":"2021","journal-title":"Am Coll Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.07.054_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.07.054_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMsr2105280","article-title":"SARS-CoV-2 variants and vaccines","volume":"385","author":"Krause","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2021.07.054_bib42","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221022179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221022179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:59:24Z","timestamp":1759273164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221022179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0190962221022179"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.07.054","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.07.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}